These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
284 related articles for article (PubMed ID: 27797891)
1. Use of Oral Anticoagulation in the Management of Atrial Fibrillation in Patients with ESRD: Con. Keskar V; Sood MM Clin J Am Soc Nephrol; 2016 Nov; 11(11):2085-2092. PubMed ID: 27797891 [TBL] [Abstract][Full Text] [Related]
2. Use of Oral Anticoagulation in the Management of Atrial Fibrillation in Patients with ESRD: Pro. McCullough PA; Ball T; Cox KM; Assar MD Clin J Am Soc Nephrol; 2016 Nov; 11(11):2079-2084. PubMed ID: 27797888 [TBL] [Abstract][Full Text] [Related]
3. Oral Anticoagulants to Prevent Stroke in Nonvalvular Atrial Fibrillation in Patients With CKD Stage 5D: An NKF-KDOQI Controversies Report. Bansal VK; Herzog CA; Sarnak MJ; Choi MJ; Mehta R; Jaar BG; Rocco MV; Kramer H Am J Kidney Dis; 2017 Dec; 70(6):859-868. PubMed ID: 28941763 [TBL] [Abstract][Full Text] [Related]
4. Nonvitamin K-dependent oral anticoagulants (NOACs) in chronic kidney disease patients with atrial fibrillation. Di Lullo L; Ronco C; Cozzolino M; Russo D; Russo L; Di Iorio B; De Pascalis A; Barbera V; Galliani M; Vitaliano E; Campana C; Santoboni F; Bellasi A Thromb Res; 2017 Jul; 155():38-47. PubMed ID: 28482261 [TBL] [Abstract][Full Text] [Related]
5. Comparative efficacy and safety of new oral anticoagulants in patients with atrial fibrillation. Schneeweiss S; Gagne JJ; Patrick AR; Choudhry NK; Avorn J Circ Cardiovasc Qual Outcomes; 2012 Jul; 5(4):480-6. PubMed ID: 22787066 [TBL] [Abstract][Full Text] [Related]
6. Comparison of the cost-effectiveness of new oral anticoagulants for the prevention of stroke and systemic embolism in atrial fibrillation in a UK setting. Zheng Y; Sorensen SV; Gonschior AK; Noack H; Heinrich-Nols J; Sunderland T; Kansal AR Clin Ther; 2014 Dec; 36(12):2015-2028.e2. PubMed ID: 25438722 [TBL] [Abstract][Full Text] [Related]
7. Use of novel oral anticoagulants for patients with atrial fibrillation: systematic review and clinical implications. Albert NM Heart Lung; 2014; 43(1):48-59. PubMed ID: 24373340 [TBL] [Abstract][Full Text] [Related]
8. A systematic review of direct oral anticoagulant use in chronic kidney disease and dialysis patients with atrial fibrillation. Feldberg J; Patel P; Farrell A; Sivarajahkumar S; Cameron K; Ma J; Battistella M Nephrol Dial Transplant; 2019 Feb; 34(2):265-277. PubMed ID: 29509922 [TBL] [Abstract][Full Text] [Related]
9. Effectiveness and Safety of Standard-Dose Nonvitamin K Antagonist Oral Anticoagulants and Warfarin Among Patients With Atrial Fibrillation With a Single Stroke Risk Factor: A Nationwide Cohort Study. Lip GYH; Skjøth F; Nielsen PB; Kjældgaard JN; Larsen TB JAMA Cardiol; 2017 Aug; 2(8):872-881. PubMed ID: 28614582 [TBL] [Abstract][Full Text] [Related]
10. Real-World Setting Comparison of Nonvitamin-K Antagonist Oral Anticoagulants Versus Vitamin-K Antagonists for Stroke Prevention in Atrial Fibrillation: A Systematic Review and Meta-Analysis. Ntaios G; Papavasileiou V; Makaritsis K; Vemmos K; Michel P; Lip GYH Stroke; 2017 Sep; 48(9):2494-2503. PubMed ID: 28716982 [TBL] [Abstract][Full Text] [Related]
11. Renal Function Considerations for Stroke Prevention in Atrial Fibrillation. Fanikos J; Burnett AE; Mahan CE; Dobesh PP Am J Med; 2017 Sep; 130(9):1015-1023. PubMed ID: 28502818 [TBL] [Abstract][Full Text] [Related]
12. Oral Anticoagulation in Patients With End-Stage Kidney Disease on Dialysis and Atrial Fibrillation. Hu A; Niu J; Winkelmayer WC Semin Nephrol; 2018 Nov; 38(6):618-628. PubMed ID: 30413255 [TBL] [Abstract][Full Text] [Related]
13. Non-vitamin K antagonist oral anticoagulation agents in anticoagulant naïve atrial fibrillation patients: Danish nationwide descriptive data 2011-2013. Olesen JB; Sørensen R; Hansen ML; Lamberts M; Weeke P; Mikkelsen AP; Køber L; Gislason GH; Torp-Pedersen C; Fosbøl EL Europace; 2015 Feb; 17(2):187-93. PubMed ID: 25236181 [TBL] [Abstract][Full Text] [Related]
14. Oral anticoagulation in atrial fibrillation: balancing the risk of stroke with the risk of bleed. Kosar L; Jin M; Kamrul R; Schuster B Can Fam Physician; 2012 Aug; 58(8):850-8. PubMed ID: 22893338 [No Abstract] [Full Text] [Related]
15. Non-Vitamin K Antagonist Oral Anticoagulants in the Treatment of Atrial Fibrillation. Fanaroff AC; Ohman EM Annu Rev Med; 2019 Jan; 70():61-75. PubMed ID: 30477393 [TBL] [Abstract][Full Text] [Related]
16. Dabigatran, rivaroxaban and apixaban vs. high TTR warfarin in atrial fibrillation. Själander S; Sjögren V; Renlund H; Norrving B; Själander A Thromb Res; 2018 Jul; 167():113-118. PubMed ID: 29803981 [TBL] [Abstract][Full Text] [Related]
17. Meta-analysis of efficacy and safety of new oral anticoagulants (dabigatran, rivaroxaban, apixaban) versus warfarin in patients with atrial fibrillation. Miller CS; Grandi SM; Shimony A; Filion KB; Eisenberg MJ Am J Cardiol; 2012 Aug; 110(3):453-60. PubMed ID: 22537354 [TBL] [Abstract][Full Text] [Related]
18. Comparative clinical outcomes between direct oral anticoagulants and warfarin among elderly patients with non-valvular atrial fibrillation in the CMS medicare population. Amin A; Keshishian A; Dina O; Dhamane A; Nadkarni A; Carda E; Russ C; Rosenblatt L; Mardekian J; Yuce H; Baker CL J Thromb Thrombolysis; 2019 Aug; 48(2):240-249. PubMed ID: 30924051 [TBL] [Abstract][Full Text] [Related]
19. Cost-effectiveness of apixaban, dabigatran, rivaroxaban, and warfarin for stroke prevention in atrial fibrillation. Harrington AR; Armstrong EP; Nolan PE; Malone DC Stroke; 2013 Jun; 44(6):1676-81. PubMed ID: 23549134 [TBL] [Abstract][Full Text] [Related]